Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
BAM15 treats mouse sepsis and kidney injury, linking mortality, mitochondrial DNA, tubule damage, and neutrophils
Naoko Tsuji, … , Peter S.T. Yuen, Robert A. Star
Naoko Tsuji, … , Peter S.T. Yuen, Robert A. Star
Published February 9, 2023
Citation Information: J Clin Invest. 2023;133(7):e152401. https://doi.org/10.1172/JCI152401.
View: Text | PDF
Research Article Nephrology

BAM15 treats mouse sepsis and kidney injury, linking mortality, mitochondrial DNA, tubule damage, and neutrophils

  • Text
  • PDF
Abstract

Sepsis pathogenesis is complex and heterogeneous; hence, a precision-medicine strategy is needed. Acute kidney injury (AKI) following sepsis portends higher mortality. Overproduction of mitochondrial ROS (mtROS) is a potential mediator of sepsis and sepsis-induced AKI. BAM15, a chemical uncoupler, dissipates mitochondrial proton gradients without generating mtROS. We injected BAM15 into mice at 0, 6, or 12 hours after cecal ligation and puncture (CLP), and these mice were treated with fluids and antibiotics. BAM15 reduced mortality, even after 12 hours, when mice were ill, and BAM15 reduced kidney damage and splenic apoptosis. Serial plasma and urinary mitochondrial DNA (mtDNA) levels increased after CLP and decreased after BAM15 administration (at 0 or 6 hours). In vitro septic serum proportionately increased mtROS overproduction and mtDNA release from kidney tubule cells, which BAM15 prevented. BAM15 decreased neutrophil apoptosis and mtDNA release; neutrophil depletion counteracted BAM15 benefits. Further, mtDNA injection in vivo replicated inflammation and kidney injury, which was prevented by BAM15. A large dose of exogenous mtDNA reversed protection by BAM15. We conclude that BAM15 is an effective preventive and therapeutic candidate in experimental sepsis and that BAM15 and mtDNA, a potential drug-companion diagnostic/drug-efficacy pair for clinical sepsis, are mechanistically linked via mtROS.

Authors

Naoko Tsuji, Takayuki Tsuji, Tetsushi Yamashita, Naoki Hayase, Xuzhen Hu, Peter S.T. Yuen, Robert A. Star

×

Figure 5

BAM15 inhibits production of mtROS in mPPTCs linked with decreasing mtDNA released from mPPTCs.

Options: View larger image (or click on image) Download as PowerPoint
BAM15 inhibits production of mtROS in mPPTCs linked with decreasing mtDN...
(A and B) Serial live-cell imaging of mtROS in mPPTCs incubated with sham or CLP serum treated with vehicle or BAM15 (10 μM or 20 μM). (A) Representative images of mtROS of mPPTCs in each group at 24 hours after incubation. Red, MitoSOX Red; blue, Hoechst 33342. Original magnification, ×400. (B) Time course of fluorescence intensity of MitoSOX Red serially measured. Data are represented as mean ± SEM. Tukey’s multiple-comparison test following 2-way ANOVA test. n = 18–31 (CLP serum+vehicle), n = 16–24 (CLP serum+BAM15, 10 μM), n = 19–24 (CLP serum+BAM15, 20 μM), n = 18–32 (sham serum+vehicle), n = 9–13 (sham serum+BAM15, 10 μM), and n = 8–13 (sham serum+BAM15, 20 μM) for 3 biological replicates per condition. *Versus each serum from mice subjected to sham surgery group, P < 0.05; †versus CLP serum+10 μM BAM15, P < 0.05; ‡versus CLP serum+20 μM BAM15, P < 0.05. (C) Time course of extracellular mtDNA levels of the supernatant shown in B. Controls were medium with CLP/sham serum or supernatants of PTCs treated with only vehicle/BAM15. #CLP serum+vehicle versus each other group, P < 0.05. Tukey’s multiple-comparison test following 2-way ANOVA test. (D) Correlation between extracellular mtDNA level and the corresponding MitoSOX Red intensity in the mPPTCs incubated with CLP serum treated with vehicle. n = 8 from 0, 6, 12, and 24 hours on 2 biological replicates. r value is Pearson’s correlation coefficient.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts